Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company. It has factories in nine countries. More than 70,000 people work for the company.

Nordisk Insulinlaboratorium was started in 1923 by the Danish Nobel laureate August Krogh, pharmacist August Kongsted and scientist Hans Christian Hagedorn. It produced insulin. In 1989 it merged with Novo Industri. 77% of Novo Nordisk's voting rights and 28.1% of its shares is owned by the Novo Nordisk Foundation.  

Novo Nordisk was Europe's most valuable company in 2023 and dominates the Danish economy. In September 2023 it was worth $421 billion. It plans to buy Inversago Pharma.

The Wegovy weight-loss drug has been very successful. It can cut the risk of heart attacks by 20% in overweight or obese patients with cardiovascular disease. It is expected to sell $7.3 billion in 2024. Ozempic, an injectable form of Semaglutide, is used to treat diabetes. It is expected to sell $16.5 billion in 2024.

Novo Nordisk specialises in diabetes care medications and devices. It also does hemostasis management, growth hormone therapy and hormone replacement therapy.

Mike Doustdar is the chief executive.

References

Other websites

 www.novonordisk.com
 www.novonordisk-us.com

Category:Pharmaceutical companies of Europe
Category:Companies of Denmark